Selected publications from the RISE Network investigators:
Guzauskas GF, Garbett S, Zhou Z, et al. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Ann Intern Med. 2023;176(5):585-595. doi:10.7326/M22-0846
Spencer SJ, Jones LK, Guzauskas GF, et al. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. J Clin Lipidol. 2022;16(5):667-675. doi:10.1016/j.jacl.2022.07.014
Jones LK, Chen N, Hassen DA, Betts MN, Klinger T, Hartzel DN, Veenstra DL, Spencer SJ, Snyder SR, Peterson JF, Schlieder V, Sturm AC, Gidding SS, Williams MS, Hao J. Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction. Circ Genom Precis Med. 2022 Oct;15(5):e003549. doi: 10.1161/CIRCGEN.121.003549. Epub 2022 Jul 12. PMID: 35862023; PMCID: PMC9584046.
Spencer SJ, Fullerton SM. Population genomic screening: Ethical considerations to guide age at implementation. Front Genet. 2022;13:899648. Published 2022 Oct 4. doi:10.3389/fgene.2022.899648
Guzauskas GF, Jiang S, Garbett S, et al. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. Genet Med. 2022;24(5):1017-1026. doi:10.1016/j.gim.2022.01.017
Graves J, Garbett S, Zhou Z, Schildcrout JS, Peterson J. Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation. Med Decis Making. 2021;41(4):453-464. doi:10.1177/0272989X21995805
Guzauskas GF, Garbett S, Zhou Z, et al. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. JAMA Netw Open. 2020;3(10):e2022874. Published 2020 Oct 1. doi:10.1001/jamanetworkopen.2020.22874
Jones, Laney, et al. “Disclosure of s Genetic Risk Variant to Familial Hypercholesterolemia Improves Adherence to Lipid Lowering Therapy.” Journal of Clinical Lipidology 14.4 (2020): 563-564.
Shi Y, Graves JA, Garbett SP, Zhou Z, Marathi R, Wang X, Harrell FE, Lasko TA, Denny JC, Roden DM, Peterson JF, Schildcrout JS. A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping. MDM Policy Pract. 2019 Aug 17;4(2):2381468319864337. doi: 10.1177/2381468319864337. PMID: 31453360; PMCID: PMC6699004.
Veenstra, D.L., Guzauskas, G., Peterson, J. et al. Cost-effectiveness of population genomic screening. Genet Med 21, 2840–2841 (2019). https://doi.org/10.1038/s41436-019-0580-4
Shi Y, Graves JA, Garbett SP, et al. A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping. MDM Policy & Practice. 2019;4(2). doi:10.1177/2381468319864337
Schildcrout JS, Denny JC, Roden DM. On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database. Drug Saf. 2017;40(1):1-2. doi:10.1007/s40264-016-0476-z
Wiley LK, Vanhouten JP, Samuels DC, et al. STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pac Symp Biocomput. 2017;22:545-556. doi:10.1142/9789813207813_0050
Schildcrout JS, Shi Y, Danciu I, et al. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. J Clin Epidemiol. 2016;72:107-115. doi:10.1016/j.jclinepi.2015.08.028
Peterson JF, Field JR, Unertl KM, et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther. 2016;100(1):67-74. doi:10.1002/cpt.331
Peterson JF, Field JR, Shi Y, et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J. 2016;16(4):393-398. doi:10.1038/tpj.2015.57
Unertl KM, Jaffa H, Field JR, Price L, Peterson JF. Clinician Perspectives on Using Pharmacogenomics in Clinical Practice . Per Med. 2015;12(4):339-347. doi:10.2217/pme.15.10